Related references
Note: Only part of the references are listed.Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients
Myron Zhang et al.
NEURO-ONCOLOGY (2016)
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma
Benjamin M. Ellingson et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria)
Nikdokht Farid et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab
Rifaquat Rahman et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
3D-PRINTED MRI-BASED CUSTOM BRAIN MOLDS FOR MINIMIZING TISSUE DISTORTION AND PRECISELY SLICING TISSUE FOR CO-REGISTRATION WITH CLINICALLY ACQUIRED MRI IN GLIOMA PATIENTS
Brian Pellatt et al.
NEURO-ONCOLOGY (2014)
Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma
Peter S. LaViolette et al.
NEURO-ONCOLOGY (2014)
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma
Kathleen M. Schmainda et al.
NEURO-ONCOLOGY (2014)
Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma
Oliver Baehr et al.
NEUROLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging
Eui Jin Hwang et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma
Peter S. LaViolette et al.
NEURO-ONCOLOGY (2013)
Restriction-spectrum aging of bevacizumab-related necrosis in a patient with GBM
Nikdokht Farid et al.
FRONTIERS IN ONCOLOGY (2013)
Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls
S. Mong et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2012)
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2012)
Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma
A. Gupta et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2011)
Exacerbation of Cerebral Radiation Necrosis by Bevacizumab
Deva Sanjeeva Jeyaretna et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2011)
Bevacizumab-Induced Diffusion Restriction in Patients With Glioma: Tumor Progression or Surrogate Marker of Hypoxia?
Johannes Rieger et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab
Elizabeth R. Gerstner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Validation of Functional Diffusion Maps (fDMs) as a Biomarker for Human Glioma Cellularity
Benjamin M. Ellingson et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2010)
Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients
Johannes Rieger et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
Andreana L. Rivera et al.
NEURO-ONCOLOGY (2010)
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
John F. de Groot et al.
NEURO-ONCOLOGY (2010)
Glioblastoma: A Method for Predicting Response to Antiangiogenic Chemotherapy by Using MR Perfusion Imaging-Pilot Study
Rahul N. Sawlani et al.
RADIOLOGY (2010)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
F. M. Iwamoto et al.
NEUROLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Whitney B. Pope et al.
RADIOLOGY (2009)
Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival
Daniel A. Hamstra et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Functional diffusion map: A noninvasive MR1 biomarker for early stratification of clinical brain tumor response
BA Moffat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
